Caladrius Biosciences (CLBS) Reports Q4 Loss of $0.73/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Caladrius Biosciences Announces 2016 Fourth Quarter and Full Year Financial Results
March 17, 2017 7:00 AM EDTAnnual revenue growth of 57% exceeds 2016 financial guidance
Conference call begins today at 8:30 am Eastern time
BASKING RIDGE, N.J., March 17, 2017 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ: CLBS) (Caladrius or the Company), a cell therapy company with a select therapeutic development pipeline focused on immune modulation and a subsidiary, PCT, a development and manufacturing partner for the cell therapy industry, announced financial results for the three and twelve months ended December 31, 2016.2016 and 2017 Year to Date Highlights
PCT:
... More